MapLight Therapeutics, Inc. (MPLT) News
Track canonical SquawkNews coverage tagged to MPLT, MapLight Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 14 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
MapLight Therapeutics announces $150 million private placement
MapLight Therapeutics announces a $150 million private placement financing.
MNA | Aug 13, 2026, 01:10 PM UTC
H
Analysts Downgrade AAPL, AKAM, AMRZ, Others
Multiple stocks downgraded by analysts
EQUITY | Aug 10, 2026, 10:51 AM UTC
L
MPLT Reiterate Buy but lower PT to $24 from $43 - Don't jump to a conclusion as Canaccord awaits Alzheimer's Disease psychosis data @ Canacc
MPLT Reiterate Buy but lower PT to $24 from $43 - Don't jump to a conclusion as Canaccord awaits Alzheimer's Disease psychosis data @ Canaccord
EQUITY | Jul 28, 2026, 01:18 PM UTC
L
Top Downgrades: ACI: NEUTRAL @ UBS CAPR: NEUTRAL @ ROTH CAT: HOLD @ Erste CLX: HOLD @ Jefferies EBC: EQUAL WEIGHT @ Stephens INTU: HOLD @ TD
Top Downgrades: ACI: NEUTRAL @ UBS CAPR: NEUTRAL @ ROTH CAT: HOLD @ Erste CLX: HOLD @ Jefferies EBC: EQUAL WEIGHT @ Stephens INTU: HOLD @ TD Cowen LAUR: UNDERWEIGHT @ MS LEVI: EQUAL WEIGHT @ WFC MPLT: EQUAL WEIGHT @ MS P
EQUITY | Jul 28, 2026, 11:11 AM UTC
H
Midday Fly By: Argenx to buy Forte, Nvidia in talks for $250B OpenAI backstop
The major averages were mixed near noon, with the Dow higher and the S&P 500 and Nasdaq in decline amid weakness in tech stocks. Still, the market has reacted positively to easing geopolitical tensions and a steep declin
MACRO | Jul 27, 2026, 03:56 PM UTC
L
MPLT (more) Maplight Therapeutics Inc - 330/6 mg once-daily (qd) dose did not achieve statistical significance on primary endpoint
MPLT (more) Maplight Therapeutics Inc - 330/6 mg once-daily (qd) dose did not achieve statistical significance on primary endpoint
EQUITY | Jul 27, 2026, 11:18 AM UTC
L
MPLT -40% premarket after trial rseults
MPLT -40% premarket after trial rseults
EQUITY | Jul 27, 2026, 11:13 AM UTC
H
MPLT, TNXP: Strong Buy
Benchmark initiates MPLT and TNXP with a strong buy rating
EQUITY | Jun 25, 2026, 10:54 AM UTC
M
MPLT: Raymond James Initiates
Raymond James initiates coverage on MapLight Therapeutics with a Strong Buy rating and a price target of $46
EQUITY | Jun 25, 2026, 09:55 AM UTC
L
MPLT Updates Board
MapLight Therapeutics announces changes to its Board of Directors
EQUITY | Jun 24, 2026, 11:00 AM UTC
M
MPLT: Needham Raises PT
Needham maintains buy rating on MapLight Therapeutics and raises price target to $42
EQUITY | Jun 22, 2026, 05:31 PM UTC
M
MPLT: Mixed Results
MapLight Therapeutics' autism drug shows mixed potential in adolescents, missing primary endpoint but demonstrating improvements in irritability among a subgroup
EQUITY | Jun 22, 2026, 05:29 PM UTC
H
MPLT: Fails ASD Trial
MapLight Therapeutics' IRIS A Phase 2 study of ML-004 in Autism Spectrum Disorder did not meet its primary endpoint
EARNINGS | Jun 22, 2026, 11:10 AM UTC
M
MPLT Reports IRIS Study Results
MapLight announces topline results from Phase 2 IRIS study for ML-004 in Autism Spectrum Disorder
EARNINGS | Jun 22, 2026, 11:01 AM UTC